FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi

{# Share Buttons Partial Variables: share_title — text to pre-fill in share dialogs share_url — canonical URL to share (use request.build_absolute_uri in parent) #}

Market Intelligence Analysis

AI-Powered
Why This Matters

FinBERT analysis of financial text showing neutral sentiment with 94.1% confidence.

Sentiment
Neutral
AI Confidence
94%
Time Horizon
Short Term

Article Context

Note: This is a brief excerpt for context. Click below to read the full article on the original source.

Johnson & Johnson said the U.S. Food and Drug Administration approved its once-daily psoriasis pill, the first oral option to rival best-selling shots.

Continue Reading
Full article on CNBC
Read Full Article
Original article published by CNBC on March 18, 2026.
Analysis and insights provided by AnalystMarkets AI.